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2Summary
The Network for Analysing Longitudinal Population-based HIV/AIDS data on Africa (ALPHA
Network, http://alpha.lshtm.ac.uk/) brings together ten population-based HIV surveillance sites in
eastern and southern Africa, and is coordinated by the London School of Hygiene and Tropical
Medicine (LSHTM). It was established in 2005 and aims to (i) broaden the evidence base on HIV
epidemiology for informing policy, (ii) strengthen the analytical capacity for HIV research, and (iii)
foster collaboration between network members. All study sites, some starting in the late 1980s and
early 1990s, conduct demographic surveillance in populations that range from approximately 20 to
220 thousand individuals. In addition, they conduct population-based surveys with HIV testing, and
verbal autopsy interviews with relatives of deceased residents. ALPHA Network datasets have been
used for studying HIV incidence, sexual behaviour and the effects of HIV on mortality, fertility, and
household composition. One of the network’s substantive focus areas is the monitoring of AIDS
mortality and HIV services coverage in the era of antiretroviral therapy. Service use data are
retrospectively recorded in interviews and supplemented by information from record linkage with
medical facilities in the surveillance areas. Data access is at the discretion of each of the participating
sites, but can be coordinated by the network.
3Data Resource Basics
The Network for Analysing Longitudinal Population-based HIV/AIDS data on Africa (ALPHA
Network) was established in 2005 and aims to (i) broaden the evidence base on HIV epidemiology
for informing policy, (ii) strengthen analytical capacity for HIV research, and (iii) foster collaboration
between study sites. 1 All of the study sites participating in the ALPHA Network are independently
managed, have their own scientific agendas and tailored research methodologies, but share a
common interest in HIV epidemiology and its interactions with the socio-demographic
characteristics of the populations they cover. The ALPHA Network study sites and their institutional
affiliations are described in Table 1, and their geographic distribution is shown in Figure 1. Several of
the ALPHA Network study sites have published site-specific profiles that contain more detail.2-10
Most of the ALPHA Network study sites are also member of the INDEPTH Network of demographic
surveillance sites (http://www.indepth-network.org/).
Figure 1: Location of the ALPHA Network member sites
The population perspective offered by the study sites complements the evidence from HIV
clinical cohorts and health facility-based studies; their longitudinal character is what sets them apart
from cross-sectional serological surveys. The activities of the network revolve around a series of
thematic workshops that lay the foundations for both site-specific and pooled analyses. Topics that
have been studied in the past include HIV incidence,11 sexual behaviour,12 orphaning and children’s
living arrangements,13 and fertility.14 The monitoring of HIV associated mortality has been, and
continues to be one of its focus areas. 15-17 The network is also well positioned to evaluate the
population-level effects of antiretroviral therapy (ART) scale-up, and member sites have recently
extended their efforts to collect more and better data on the uptake of HIV diagnostic and AIDS care
services.
The ALPHA Network is a regular contributor to the UNAIDS Reference Group on Estimates,
Modelling and Projections (http://www.epidem.org), which oversees the data and methods used for
producing HIV estimates for most countries in the world, and to the modelling community through
an agreement with the HIV Modelling Consortium (http://www.hivmodelling.org/).
4Table 1: Description of the ALPHA Network study sites
5Data collected
The ALPHA Network pools and harmonizes data from member sites that conduct
demographic surveillance in populations that range from approximately 20,000 to 220,000 in size.
Most study sites cover the entire population in one contiguous area, but some members conduct
surveillance in multiple areas to represent distinct socioeconomic zones (e.g., Manicaland).
Surveillance is generally conducted via household visits and interviews with one of the household
members – sometimes referred to as proxy-respondents – who report on births, deaths in- and out-
movements in the household in the intercensal period. The Karonga demographic surveillance is an
exception, and is done by means of village informants with an annual census to check on reporting
completeness.2 In most study sites, the enumerated population includes all resident members of
households in the surveillance area. The two South African study sites (uMkhanyakude and
Agincourt) are characterized by high levels of temporary or circulatory migration, and both resident
and non-resident members of households are enumerated (non-resident household members are
included in the ALPHA Network datasets for Agincourt only). 18, 19 With the exception of the study
sites in Nairobi and Ifakara, the ALPHA Network member sites are predominantly rural, and they all
have relatively young age structures (Figure 2). In some of the settings the population age structure
is marked by high levels of out-migration (e.g., Masaka and uMkhanyakude).
Figure 2: Relative age distribution by study site, sex and HIV status, 2011
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The ALPHA Network assembles data from different sources, including demographic
surveillance, verbal autopsy interviews, serological and sexual behaviour surveys, and individually-
linked data from medical facilities. The starting date and intervals of data collection are summarized
in Table 1. Demographic surveillance generates data about residence episodes and the starting (birth
and in-migration) and terminating (migration and death) events of residence episodes. Most study
sites routinely follow up the report of deaths in the household with a verbal autopsy (VA) interview
for determining the underlying and immediate causes of death. VA instruments were developed
independently, and have over the years converged towards the standard VA questionnaire proposed
7by the WHO. 20 VA questionnaires typically include retrospective questions about the HIV status of
the deceased, and many study sites now also inquire about HIV services use.
Along with the demographic surveillance, ALPHA Network study sites organize repeated
population-based HIV serosurveys, either using home visits or temporary HIV testing centres to
which residents are invited. HIV testing eligibility criteria vary across sites, and some of the study
sites have restricted testing to a sample of the adult population (Nairobi and Agincourt).
HIV testing protocols and participation rates vary between sites and over time. Prior to the
availability of rapid HIV tests, test results were returned to participants who requested them at the
household or temporary clinic a few weeks later. In recent serosurveys, residents are usually given
an opportunity to receive standard HIV Testing and Counselling (HTC) in the same visit that
specimens for a research test are collected. The Manicaland study offered free HIV tests for
diagnostic purposes at a local antenatal clinic. Some of the ALPHA Network members have published
studies describing the HIV serosurveys, non-response in the HIV serosurveillance and associated bias
in HIV prevalence estimates.21-25 The serosurveys also create an opportunity to administer an
individual interview on sexual behaviour, health services utilization, etc.
A few of the ALPHA Network sites have established record linkage between the demographic
surveillance and medical facility data via a unique (set of) identifier(s) (e.g., Karonga, uMkhanyakude,
Rakai and Masaka) while others including Kisesa, Kisumu and Agincourt have piloted probabilistic
record linkage.26 A more recent initiative, currently implemented in Agincourt and Kisesa, is to
conduct the record linkage in the presence of the patient at the time that he or she visits the health
facility. This protocol has the advantage that the patient can confirm his or her identity and that
ensures better-quality matches. In addition, the presence of the patient offers an opportunity to
seek informed consent for linking medical information to the demographic surveillance database.
Linked medical facility data are used to retrieve information on HIV status, and HIV care and
treatment services use, and in some cases also clinical markers of disease progression and viral
suppression.
Essential (input) data for estimating mortality, HIV incidence and prevalence are the
residence episodes and HIV test results. These data are updated on a regular basis, and to that end,
we have developed a series of metadata templates that are used to guide the study sites on the
structure and attributes of the data they contribute to the ALPHA Network.  Metadata templates
have also been developed for parent-child links, fertility, respondent background characteristics,
verbal autopsy data, and self-reported and clinic data on the use of HIV care and treatment services.
Metadata templates are available through the ALPHA Network website (see below).
The allocation of person-time to HIV status (and treatment) categories is study-specific. In
analyses of mortality, we generally classify time prior to the first recorded HIV test as HIV status
unknown. Failure to do so would introduce downward bias in mortality estimates as only survivors
can be tested. The time following a positive test remains positive until censoring or death. Studies
often also allow for exposure time following a negative test in order to estimate mortality among
HIV negative individuals, but the period is sufficiently short to ensure that elevated mortality among
seroconvertors does not introduce upward bias. Similar rules for imputing and stale-dating
information are used in studies focusing on other personal attributes (e.g., marital status).
Table 2 summarizes the person-years of exposure and number of deaths by HIV status and,
for people living with HIV (PLHIV), the stage on the HIV care and treatment cascade. All sites
measure HIV infection, ART initiation and death. Some of the study sites can also distinguish
between seroconversion and the receipt of an HIV positive diagnosis, between PLHIV who are in care
and those who are not, and between those who ever interrupted treatment and those who have
been on ART continuously.
8Table 2: Descriptive statistics of the pooled ALPHA dataset, 1990-2011
The breakdown of the study populations by HIV status is shown in Figure 2. It illustrates that
the coverage of the HIV status information differs considerably across study sites. These differences
result from variation in the eligibility criteria for HIV testing, frequency of testing, and HIV testing
participation rates. In addition, some study sites retrieve HIV status information through record
linkage with treatment facilities (Table 1). The latter also explains the small number of known HIV
positive children in uMkhanyakude even though they were not eligible for participation in the
serosurveys. Record linkage with treatment facilities can only identify HIV positive residents, and
that tends to inflate HIV prevalence in the dataset. Point prevalence of HIV is therefore more
appropriately estimated from the serological surveys (ideally with a correction for non-response
bias).21
Data Resource Use
Early studies from ALPHA sites documented the severe impact of HIV on adult mortality.27-30
Later, data from the ALHA Network’s members established that the survival of HIV positives in the
absence of ART was similar to that of high income countries, including the shorter survival of people
infected at older ages, and the absence of gender differences in the survival post infection once the
age at infection was taken into account. 15, 31 These estimates of the survival of PLHIV who are not
receiving treatment are incorporated in the Spectrum model,32-34 which is the tool used by UNAIDS
for generating national and global estimates of the HIV/AIDS epidemic. Similarly, long term follow-up
of children has allowed the ALPHA Network to contribute evidence on the survival patterns of
infected and uninfected children of HIV positive mothers, 35 and has demonstrated that a mother’s
death can have as important an impact on a child’s short-term probability of dying as the mother’s
HIV infection. 36
More recently, the ALPHA Network member sites have registered important population-
level mortality reductions following the introduction of ART. 16, 37-40 Crude death rates among adult
PLHIV across all study sites have more than halved, from 74.52 per 1,000 in 1990-2003 (95%-
Confidence interval (CI): 71.22-77.96) to 31.71 in 2009-2011 (95%-CI: 30.38-33.1) (Table 2).
Continued improvements in the timing of ART initiation have not only reduced the mortality of
PLHIV receiving treatment, but also reduced mortality of those who have not (yet) started ART
because they are increasingly selected for early stage disease.38 Figure 3 further illustrates that the
9mortality rates of PLHIV on ART were often very high as treatment was just being rolled out because
a backlog of patients with severe immunosuppression were quickly ushered onto treatment as it
became locally available. As ART programs matured, the mortality rates of PLHIV on ART declined
and so did the fraction of deaths to PLHIV during the first six months of treatment (Figure 3). Both of
these statistics are indicative of improvements in the timing of treatment initiation and the clinical
management of patients. The bar graph in Figure 3 also suggests, however, that a large fraction –
the majority in Masaka – of the deaths to PLHIV occur among men and women without a record of
treatment initiation. Such deaths are not usually captured in clinic-based studies, and that is where
the ALPHA study sites fill an important information gap.
Figure 3: Deaths and death rates of adult PLHIV (ages 15-65) by treatment status, Masaka (UGA)
and uMkhanyakude (RSA)
Despite sizable declines, mortality among PLHIV remains relatively high: in 2009-2011, the
crude death rate among adult PLHIV (31.71 per 1,000, 95%-CI: 30.38-33.1) was still more than three
times higher than the death rate of known HIV negative adults (9.57 per 1,000, 95%-CI: 9.21-9.95,
Table 2). Verbal autopsy studies from the ALPHA Network sites have demonstrated that HIV and TB
continue to account for a large share of deaths among PLHIV, which suggests that HIV services use
remains sub-optimal. These studies also suggest, however, that PLHIV have elevated mortality rates
from a wide range of causes, including some that are not immediately suggestive of HIV.41 42
Mortality reductions among PLHIV have generally been larger for women than for men,38
and that is thought to be associated with women’s greater engagement with HIV services. However,
the remaining burden of HIV-related mortality –as measured by the adult life-years lost to HIV–
remains higher for women than for men. Women’s higher HIV prevalence, younger ages at infection,
and lower mortality rates from other causes all contribute to this phenomenon.43
ALPHA network study sites have also provided direct evidence about HIV incidence in
community-based, non-trial settings, and these measurements have been used to validate indirect
estimation methods based on models,11 and methods based on incidence assays.44 Contrary to the
expectations raised by studies of discordant couples,45 so far only one ALPHA site has shown a
population-level decline in HIV incidence associated with ART roll-out,46. A comprehensive list of
publications is maintained on the ALPHA Network website.
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Strengths and Weaknesses
The ALPHA Network assembles anonymised data from large population-based HIV
surveillance sites in sub-Saharan Africa and is an important resource for studying the epidemiology
of HIV. Because demographic surveillance sites cover relatively small populations, however, their
findings cannot be easily extrapolated to entire countries or regions. This critique applies in varying
degrees to the ALPHA Network study sites, but their justification stems from a conscious decision to
prioritize data quality and repeated measurement over national representativeness. Generalizability
of findings can be compromised further if study sites are used to embed trials or are serviced by
superior medical facilities.47 Pooling of the data from across the ALPHA Network overcomes some of
the aforementioned critiques, as findings are more convincing whenever they can be reproduced in
distinct locations with dissimilar epidemiological and socioeconomic profiles, and different fieldwork
practices. The ALPHA Network’s added value is fully brought to bear in analyses that require the
statistical power of a pooled dataset. Examples include the estimation of HIV associated maternal
mortality,48 and a study on the risks of acquiring HIV infection during pregnancy.14
Because the ALPHA Network brings together data from various demographic surveillance
sites, it shares many of their challenges. These include high population mobility (internal and
external, and both temporary migration and population movements with a more permanent
character), the limitations arising from proxy respondent reporting, and survey fatigue. Challenges
particular to a network of surveillance sites are the standardization and documentation of datasets.
Data extraction and transformation to the ALPHA meta-data specifications relies on the correct
interpretation of the data specifications and an understanding of the site’s contemporary and
historical data collection procedures and instruments. Personnel and study protocols often change
over time, and transforming these diverse data to a standard format is both challenging and time
consuming. Work is ongoing to document these data extraction and transformation procedures in
detail.
The integration of demographic surveillance with health facility data is an important and
relatively recent enhancement of the ALPHA Network’s data repository for policy-relevant analyses,
but it is a logistically and ethically challenging enterprise. For example, most of the health facilities in
the study sites do not keep electronic patient records and do not have centralized patient
administration. In addition, most health facilities are independently managed and the interface
between research and health services provision has to be carefully negotiated with respective
authorities.
Data Resource Access
The ALPHA Network regularly provides aggregate data tables and estimates to the UNAIDS
Reference Group on Estimates, Modelling and Projections, and the HIV Modelling Consortium.
Individual-level demographic data from most ALPHA Network member sites are available through
INDEPTH’s iShare repository (http://www.indepth-ishare.org ). Further, the ALPHA Network has
made a commitment to deposit a subset of the individual-level data in a public repository by the end
of this funding cycle, and work is ongoing to develop a mechanism to facilitate the use of data that
are not open access. Meanwhile, access to micro-data is at the discretion of each participating study
site but data requests may be channelled through the network co-ordinating group at LSHTM. Data
requests including a short description of their purpose should be sent to alpha@lshtm.ac.uk.
More information about the ALPHA Network, including a detailed description of the metadata are
available on the ALPHA Network website: http://alpha.lshtm.ac.uk.
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Funding
The core funding for the network comes from the Wellcome Trust (085477/Z/08/Z), and is
administered by the London School of Hygiene and Tropical Medicine (LSHTM). At its inception in
2005, the network consisted of six study sites. The network is now in its second Wellcome Trust
funding cycle and has grown to ten study sites. Additional funding has been received from the Bill
and Melinda Gates Foundation (2013, BMGF- OPP1082114) for monitoring HIV related mortality in
the era of ART, and the Nuffield Foundation (2012) for studying the effects of HIV on children and
adolescents. UNAIDS and WHO have supported various ALPHA Network meetings and publications.
ALPHA Network in a nutshell:
 The ALPHA Network brings together ten population-based HIV surveillance sites in
eastern and southern Africa. It was established in 2005 and aims to strengthen the
analytical capacity for HIV research through collaboration, and broaden the evidence
base on HIV epidemiology for policy.
 Member sites monitor vital events, HIV infection and health services utilisation in
populations that range from approximately 20,000 to 220,000 thousand individuals.
These jointly contribute over 6 million person-years of exposure time, and over 140,000
person-years by people who are known to be HIV positive.
 The ALPHA Network is an important resource for population-level monitoring of the HIV
epidemic, the impact of prevention and treatment programmes and their downstream
effects on individuals and families.
 Access to microdata is at the discretion of each of the study sites but may be channelled
through the network co-ordinating group at LSHTM. More information about the
ALPHA Network and contact details are available on its website:
http://alpha.lshtm.ac.uk
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